文献速递神经外周血管CTDSA

未接种疫苗的COVID-19患者再灌注后梗死持续增长与缺血半暗带消耗:病例对照研究

Continued Infarction Growth and Penumbral Consumption After Reperfusion in Vaccine-Naive Patients With COVID-19: A Case-Control Study.
PubMed 文献 · AJR Am J Roentgenol · 2023-05-17

回顾性比较100例COVID-19合并急性缺血性卒中患者与282例无COVID-19的卒中患者,均行CT灌注后血管内治疗。COVID阳性患者最终梗死体积中位数77.8 mL显著大于对照18.2 mL(p=0.01),校正模型中COVID阳性为梗死持续增长的显著预测因子(OR 5.10,95%CI 1.00-25.95;p=0.05)。

要点

  • COVID-19合并大血管闭塞卒中患者血管再通后梗死体积仍显著大于无COVID-19患者(中位数77.8 mL vs 18.2 mL,p=0.01)。
  • COVID阳性是梗死持续增长的独立预测因子(OR 5.10,95%CI 1.00-25.95;p=0.05),提示再灌注后仍应关注梗死进展。
  • 基线CT灌注显示COVID阳性患者初始梗死核心和总低灌注体积数值均高于对照,但原文未报告组间统计学比较。

核心结论

  • 研究结果支持COVID-19患者脑血管事件临床过程可能更具侵袭性,提示血管造影再通后仍存在较大的梗死增长和缺血半暗带组织持续消耗。

研究设计与样本

  • 回顾性病例对照研究,比较2020年3月至2021年4月连续100例COVID-19合并急性缺血性卒中患者与同期282例无COVID-19的卒中患者;再灌注分级按eTICI评分二分为阳性(2c-3分)和阴性(<2c分)组;所有患者先行CT灌注成像记录梗死核心和总低灌注体积,后接受血管内治疗。最终纳入10例COVID阳性患者(平均年龄67±12岁;男7例、女3例)和144例COVID阴性患者(平均年龄71±16岁;男76例、女68例),均有基线CT灌注和随访影像。

诊断标准与关键数值

  • 再灌注阳性定义为eTICI评分2c-3分,阴性定义为eTICI评分<2c分;COVID阴性患者初始梗死核心体积均值±SD为1.5±18 mL、总低灌注体积为85±100 mL,COVID阳性患者分别为30.5±34 mL和117±80.5 mL;最终梗死体积中位数COVID阳性77.8 mL vs 对照18.2 mL(p=0.01);校正logistic参数回归模型中COVID阳性预测梗死持续增长的OR为5.10(95%CI 1.00-25.95;p=0.05)。

临床应用与阅片要点

  • 作者认为,SARS-CoV-2感染可能在未接种疫苗的大血管闭塞急性缺血性卒中患者中,尽管血管造影再灌注仍促进梗死持续进展;这些发现对再灌注患者的预后判断、治疗选择和梗死增长监测具有潜在意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Neurologic sequelae of SARS-CoV-2 include potentially malignant cerebrovascular events arising from complex hemodynamic, hematologic, and inflammatory processes occurring in concert. OBJECTIVE. This study concerns the hypothesis that despite angiographic reperfusion COVID-19 promotes continued consumption of at-risk tissue volumes after acute ischemic stroke (AIS), yielding critical insights into prognostication and monitoring paradigms in vaccine-naive patients experiencing AIS. METHODS. This retrospective study compared 100 consecutive COVID-19 patients with AIS presenting between March 2020 and April 2021 with a contemporaneous cohort of 282 AIS patients without COVID-19. Reperfusion classes were dichotomized into positive (extended thrombolysis in cerebral ischemia [eTICI] score = 2c-3) and negative (eTICI score < 2c) groups. All patients underwent endovascular therapy after initial CT perfusion imaging (CTP) to document infarction core and total hypoperfusion volumes. RESULTS. Ten COVID-positive (mean age ± SD, 67 ± 12 years; seven men, three women) and 144 COVID-negative patients (mean age, 71 ± 16 years; 76 men, 68 women) undergoing endovascular reperfusion, with antecedent CTP and follow-up imaging, comprised the final dataset. Initial infarction core and total hypoperfusion volumes (mean ± SD) were 1.5 ± 18 mL and 85 ± 100 mL in COVID-negative patients and 30.5 ± 34 mL and 117 ± 80.5 mL in COVID-positive patients, respectively. Final infarction volumes were significantly larger in patients with COVID-19, with median volumes of 77.8 mL versus 18.2 mL among control patients (p = .01), as were normalized measures of infarction growth relative to baseline infarction volume (p = .05). In adjusted logistic parametric regression models, COVID positivity emerged as a significant predictor for continued infarct growth (OR, 5.10 [95% CI, 1.00-25.95]; p = .05). CONCLUSION. These findings support the potentially aggressive clinical course of cerebrovascular events in patients with COVID-19, suggesting greater infarction growth and ongoing consumption of at-risk tissues, even after angiographic reperfusion. CLINICAL IMPACT. SARS-CoV-2 infection may promote continued infarction progression despite angiographic reperfusion in vaccine-naive patients with large-vessel occlusion AIS. The findings carry potential implications for prognostication, treatment selection, and surveillance for infarction growth among revascularized patients in future waves of infection by novel viral strains.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Dehkharghani, Vogel, Jandhyala, et al. Continued Infarction Growth and Penumbral Consumption After Reperfusion in Vaccine-Naive Patients With COVID-19: A Case-Control Study. AJR Am J Roentgenol. 2023. PMID: 37195793. doi:10.2214/AJR.23.29296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。